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Background: High mobility group box 1(HMGB1) overexpression has been reported in a variety of human cancers.
However, the role of HMGB1 in hepatocellular carcinoma (HCC) remains unclear. The aim of present study was to
analyze HMGB1 protein expression in tumor, para-tumor and normal tissue and to assess its prognostic significance
for HCC after curative hepatectomy.
Methods: The levels of HMGB1 mRNA and protein in tumor, para-tumor and normal tissue were evaluated in 11
HCC cases by Reverse Transcription-polymerase chain reaction (RT-PCR) and Western blot. Additionally, HMGB1
protein expression in 161 HCC was analyzed by immunohistochemistry and correlated with clinicopathological
characteristics and survivals. Student’s t-test, spearman’s rank correlation, Kaplan-Meier plots and Cox proportional
hazards regression model were used to analyze the data.
Results: By RT-PCR and Western blot, the levels of HMGB1 mRNA and protein were significantly higher in HCC,
compared to that in para-tumor (p< 0.001) and normal tissue (p< 0.001). Immunohistochemical staining revealed
that high expression of HMGB1 was detected in 42.9% (69/161) HCC cases. High expression of HMGB1 was
significantly associated with incomplete encapsulation (p= 0.035) and advanced TNM stage (p= 0.036). Multivariate
analysis showed that high expression of HMGB1 was an independent prognostic factor for both overall (p= 0.009,
HR = 1.834, 95%CI: 1.167-2.881) and disease-free survival (p= 0.018, HR = 1.622, 95%CI: 1.088-2.419), along with tumor
size. Subgroup analysis revealed that high expression of HMGB1 predicted poorer overall survival only for tumor
>5 cm (p= 0.031), but not for tumor ≤5 cm (p= 0.101).
Conclusions: HMGB1 protein might contribute to the malignant progression of HCC, high expression of HMGB1
predicts poor prognosis for patients with HCC after curative hepatectomy, especially for patients with tumor
>5 cm.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and the third most frequent
cause of death of cancer. Although the majority of cases
are still found in Asia and Africa, recent evidence has
shown that the incidence and mortality rate of HCC are
rising in North America and Europe [1]. Liver resection
is still considered to be the mainly curative therapy for
HCC, with about 50-70% 5-year overall survival after
curative hepatectomy. However, the postoperative recur-
rence rate remains as high as 70%-83.7% [2,3]. There-
fore, it is critical to identify prognostic factors for
patients with HCC after hepatectomy. Unfortunately, at
present, we are unable to prognosticate accurately on
the basis of commonly used clinicopathological charac-
teristics [1-4].
High mobility group box 1(HMGB1), an evolutionarily
ancient protein, is a nuclear DNA-binding protein that
loosely binds to chromatin and presents in almost all
eukaryotic cells [5]. The nuclear role of HMGB1 is not
only to integrate and stabilize nucleosome by means of
making DNA bending and facilitating the bind of several
regulatory protein complexes to DNA, such as the nu-
clear factor-κB (NF-κB), p53, p73 transcriptional com-
plexes [6,7], but also to facilitate the integration of
transposons [8], to regulate transcriptional activation [9].
Moreover, HMGB1 can be released from necrotic cells,
activated macrophages, mature dendritic cells and nat-
ural killer cells to mediate late systemic inflammation
which makes it one of the main prototypes of the emer-
ging damage-associated molecular pattern molecules
[10-12]. HMGB1 plays corresponding roles in cells
through its receptors: RAGE (receptor for advanced gly-
cation end-products) and TLRs (Toll like receptors). Re-
cent studies have revealed that the binds of HMGB1 and
RAGE or TLRs are involved in the activation of several
pathways, such as NF-κB pathway, PI3K/AKT pathway,
as well as signal transduction through AKT, ERK and
p38 [13-16].
The connection that widely exists between HMGB1
and intracellular signal pathways makes HMGB1 can
function during inflammation, cell differentiation and
migration, tumor invasion and metastasis [17]. High ex-
pression of HMGB1 has been showed to be a strong pre-
dictor of poor survivals in kinds of malignancies,
including colorectal cancer, gastric cancer, nasopharyn-
geal carcinoma, and squamous-cell carcinoma of the
head and neck et al [18-21]. More recently, Jiang W et al
[22] reported that HMGB1 was associated with clinico-
pathologic features in patients with hepatocellular car-
cinoma, but the role of HMGB1 in predicting prognosis
of HCC after curative hepatectomy remains unclear. In
present study, we evaluated the expression of HMGB1
in tumor, para-tumor and normal tissue, to assess itsprognostic significance in HCC patients after curative
hepatectomy.
Methods
Patients and clinical specimens
To detect the mRNA and protein level of HMGB1 in
tumor, para-tumor (defined as ≤2.0 cm distance from
tumor edge) and normal (defined as >2.0 cm distance
from tumor edge) tissue, fresh tissues were collected
from 11 patients with HCC who underwent hepatect-
omy between Sep 2011 and Oct 2011 in our department,
Department of Hepatobiliary Surgery, Cancer Centre of
Sun Yat-Sen University (Guangzhou, China).
A cohort of consecutive 161 previously untreated
patients who received curative hepatectomy for HCC in
our department from Jan 2004 to Dec 2005 was enrolled.
All patients were confirmed by histological diagnosis. In
present study, curative hepatectomy was defined as fol-
lowed: 1) microscopically complete removal of the
tumor; 2) ≤3 tumors, no vascular and bile duct invasion;
3) no lymph node or distance metastasis. For the use of
these clinical materials for research purposes, prior
patient’s consent and approval from the Ethics Commit-
tee of Cancer Centre of Sun Yat-Sen University were
obtained.
The main clinical and pathological variables of all
patients were described in detail in Table 1. In brief,
there were 140 male and 21 female patients, with a me-
dian age of 48 years old (mean ± SD: 46.1 ± 11.5, range:
14-70). Tumor size ranged from 1.5 cm to 24.0 cm
(mean ± SD: 6.3 ± 4.1), 85 patients (52.8%) had tumor
≤5.0 cm and 76 (47.2%) had tumor >5.0 cm. 147
patients (91.3%) had single tumor and 14 (8.7%) had 2-3
tumors. 144 patients (89.4%) had HBV infection, and
only one patient had HCV infection. According to the
7th edition tumor-node-metastasis (TNM) classification
of the American Joint Committee on Cancer (AJCC)
[23], 131 patients (81.4%) had stage I disease, 11 (6.8%)
had stage II disease, and 19 (11.8%) had stage III disease
respectively (Table 1).
Reverse transcription-polymerase chain reaction (RT-PCR)
Surgical specimens were processed immediately after op-
eration. Total RNAs were extracted from tissues by using
Trizol reagent (Invitrogen, Carlsbad, USA) according to
the manufacturer’s protocol. All procedures were per-
formed with i-cyclor. 1.0 g of total RNA was transcripted
with River-Tra Ace (Toyobo, Tokyo, Japan), Oligo (dT)
20, RNase inhibitor, 5-RT buffer, and dNTP mixture. RT-
PCR was performed at 42°C for 20 min and then at 95°C
for 5 min using 1.0 g of RNA per reaction. The cDNA
was amplified with TaKaRa Taq (TaKaRa, Ootsu, Japan),
according to the manufacturer’s protocol. The PCR pro-
ducts were separated by electrophoresis using 1.5%
Table 1 Correlations between HMGB1 expression and clinicopathalogic characteristics in 161 patients with HCC
Variables All Patients (n = 161) High HMGB1 (n = 69) Low HMGB1 (n= 92) P value
Age(mean± SD, year) 46.1 ± 11.5 44.9 ± 11.6 48.1 ± 11.3 0.511
≤55 128 59 69 0.103
>55 33 10 23
Gender 0.639
Male 140 61 79
Female 21 8 13
HBV infection 0.377
Absent 17 9 8
Present 144 60 84
AFP level 0.785
≤400 ng/ml 89 39 50
>400 ng/ml 72 30 42
Liver cirrhosis
Absent 22 9 13
Present 139 60 79
Child-pugh 0.403
A 158 67 91
B 3 2 1
Tumor size(mean± SD, cm) 6.3 ± 4.1 6.0 ± 3.6 6.5 ± 4.5 0.075
≤5 cm 85 36 49 0.892
>5 cm 76 33 43
Tumor number
Single 147 62 85 0.575
2-3 14 7 7
Tumor encapsulation 0.035
Complete 71 37 34
Incomplete 90 32 58
TNM stage 0.036
I 131 51 80
II-III 30 18 12
Tumor differentiation
I-II 67 23 44 0.066
III-IV 94 46 48
HBV: hepatitis B virus, AFP: alpha fetoprotein, HMGB1: high mobility group box 1.
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and visualized by ethidium bromide staining for 10 min
and ultraviolet illumination (Kodak, New Haven, USA).
The following specific primers were used: HMGB1,
sense strand: 5’-TATGGCAAAAGCGGACAAGG-3’,
antisense strand: 5’- CTTCGCAACATCACCAATGGA-3’;
GAPDH, sense strand: 5’-ATCAGCAATGCCTCCTGCAC-
3’, antisense strand: 5’-CGTCAAAGGTGGAGGAGTGG-3’.
Human GAPDH served as an internal control for the ef-
ficiency of mRNA isolation and cDNA synthesis.Western blot analysis
The fresh tissues were clipped, washed three times with
ice-cold phosphate-buffered saline (PBS), and then the
samples were lysed on ice in RIPA buffer with protease
inhibitors and quantified to the same amount (30 μg).
The proteins were separated by 12% SDS–PAGE and
transferred to a PVDF membrane (GE healthcare, USA).
After being blocked with 5% milk for 1 hour at room
temperature, the membranes were then incubated over-
night at 4°Cwith anti-HMGB1 (1:500) (Abcam,Cambridge,
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nology, USA) antibodies. Followed by anti-mouse or rabbit
horseradish peroxidaseconjugated IgG, an ECL kit (GE
healthcare,USA)wasused for detection.Immunohistochemistry (IHC)
The expression of HMGB1 in tumor tissues of the co-
hort of 161 patients, as well as 60 available para-tumor
tissues from the same cohort, was examined by Immu-
nohistochemistry (IHC). The samples were fixed by for-
malin, embedded in paraffin and cut into 4-μm thick
sections. Then, the sections were de-waxed in xylene
and rehydrated with ethanol arranged a graded concen-
tration. After blocked with 0.3% hydrogen peroxide, the
antigens were retrieved in a microwave in 10 mM citrate
buffer (pH 6.0) for 30 minutes and cooled to room
temperature. After washing with PBS, the sections were
incubated overnight at 4°C with mouse monoclonal anti-
body against human HMGB1 with a dilution of 1:300
(Abcam, Cambridge, MA, USA). Subsequently, horse-
radish peroxidase conjugated secondary antibody was
used. The sections were developed with diaminobenzi-
dine tetrahydrochloride (DAB) and counterstained with
hematoxylin. As-known HMGB1 positive colorectal can-
cer specimens were selected as positive controls [24].
Negative controls were employed in which the primary
antibody was replaced by PBS.IHC evaluation
To estimate the expression of HMGB1, five fields were
selected and at least expression of 1,000 tumor cells in
sum, the evaluation used a high-power microscopy. The
expression of HMGB1 in HCC was scored with the pro-
portion of positive cells and using intensity. We ranked
the proportion of positive cells into 4 categories: 1
(≤25%), 2 (26%-50%), 3 (51%-74%), and 4 (≥75%). Then
we evaluated the intensity of nuclear or cytoplasmic
staining and grouped them into the following four cat-
egories: no staining/background of negative controls
(score = 1), weak staining detectable above background
(score = 2), moderate staining (score = 3), and intense
staining (score =4). The index was obtained by multiply-
ing the intensity and percentage scores, the results as
below: (-), (+), (++), (+++), (++++) indicated multiply-
indexes of 1-2, 3-4, 6-8, 9-12 and 16, respectively; (-),
(+), (++) were defined as low expression, and (+++) and
(++++) were defined as high expression. Each section
was independently scored by two pathologists. If an in-
consistency occurred, a third pathologist was consulted
to achieve consensus. The IHC score methods were
identical for tumor and para-tumor tissues. This evalu-
ation method was modified from the method used by
Peng et al [24].Follow up
Follow-up of patients included physical examination,
routine laboratory testing, and contrast-enhanced ab-
dominal computed tomography every 3 months in the
first 2 years, and every 6 months in 3 to 5 years after
surgery, then every year thereafter. At each follow-up
visit, liver function tests and alpha fetoprotein (AFP)
were determined. Chest radiography was done every
6 months to observe lung metastasis. If necessary, CT of
the chest, bone scintigraphy and positron emission tom-
ography (PET) were also performed for the diagnosis of
metastasis and/or recurrence. The last follow-up date
for patients still alive was November 2011.
Causes of death and sites of recurrence were deter-
mined from death certificates, medical interviews, and
radiological findings. Overall survival was defined as the
interval between the time of hepatectomy to death or to
the last date of follow-up. Disease-free survival time was
between the time of hepatectomy and the time when re-
currence was diagnosed or to the time of the last follow-
up. The treatment for recurrent tumor was determined
by our multidisciplinary team (MDT) including sur-
geons, oncologists, radiologists, gastroenterologists, and
pathologists.
Statistical analysis
The statistical analyses were performed using the SPSS
13.0 statistical software (SPSS Company, Chicago, Illinois,
USA). Comparisons between 2 groups were done using
the student’s t-test for continuous data and the Chi square
test for categorical data. The correlation between the
HMGB1 expression and clinicopathologic characteristics
were analyzed with the Chi square test. The overall and
disease-free survivals were calculated by Kaplan-Meier
method and compared by log-rank test. The prognostic
varieties in predicting overall and disease-free survival
were assessed by multivariate Cox proportional hazards
regression analysis. Results were given as mean ± S.D.
All statistical tests were two-sided, and a significant dif-
ference was considered when p< 0.05.
Results
Increased HMGB1 mRNA and protein expression in HCC
tissue
The expression of HMGB1 mRNA and protein were
detected and analyzed in all fresh tissues from 11 HCC
patients. The RT-PCR results showed that HMGB1 mRNA
level was significantly higher in tumor tissue, compared to
that in para-tumor tissue (0.848±0.075 Vs 0.446±0.102,
p< 0.001) and that in normal tissue (0.848±0.075 Vs
0.354±0.081, p< 0.001). The Western blot analysis of
HMGB1 protein also showed that the expression of
HMGB1 protein was significantly higher in tumor tissue,
compared to that in para-tumor tissue (0.781±0.105 Vs
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(0.781±0.105 Vs 0.180±0.062, p< 0.001, Figure 1).
Immunohistochemistry was performed in all 161
paraffin-embedded, archival HCC tumor samples and in
available 60 para-tumor samples. Positive HMGB1 immu-
nostaining was predominantly observed in the cytoplasm
of carcinoma cell, and rarely in nucleus. High expression
of HMGB1 was detected in 69/161(42.9%) of tumor tis-
sues, and only 5/60(8.3%) in para-tumor tissues (Figure 2).
Among tumor samples, HMGB1 expression was scored
1–2 in 13 (8.1%), 3–4 in 21 (13.0%), 6–8 in 58 (36.0%), 9–
12 in 50 (31.1%) and 16 in 19 (11.8%) specimens.
Correlation of HMGB1 protein expression with the
clinicopathologic characteristics
The association between HMGB1 protein expression
and clinicopathological characteristics of HCC wasa
c
Figure 1 RT-PCR and Western blot analysis of HMGB1 expression in n
fresh tissues. (a) Representative RT-PCR results of two cases, and (c) Repre
HMGB1 mRNA expression, and (d) protein expression. Each value which rep
GAPDH served as an internal control, the gray-scale comparison between H
western blot results. * p< 0.001, compare to normal (N) and para-tumor (Pexplored by the Chi square test. As it was showed in
Table 1, high expression of HMGB1 was significantly
associated with incomplete encapsulation (p= 0.035) and
advanced TNM stage (p= 0.036). However, no significant
relationship was found between HMGB1 protein expres-
sion and variables such as gender, age, HBV infection,
alpha fetoprotein (AFP) level, underlying liver cirrhosis,
Child–Pugh classification, tumor size, tumor number
and tumor differentiation (Table 1).
Correlation of HMGB1 protein expression with survivals
The mean follow-up period was 47.5± 17.9 months (range
6.0-87.0 months). At the end of follow up, there were 78
deaths and 83 survivals. The 1, 3, 5-year overall survival of
the whole group was 86.9%, 64.4% and 51.7% respectively.
Univariate analysis showed that the overall survival was
directly influenced by tumor size (p=0.005), tumorb
d
ormal (N), para-tumor (P) and tumor tissue (T) of all 11 HCC cases
sentative Western blot results of two cases. (b) Relative quantity of
resents the average of 11 cases expressed as the mean± SE. Human
MGB1 and GAPDH was used to quantify the bands of RT-PCR and
).
Figure 2 Representative immunohistochemical staining of HMGB1 in tumor and para-tumor tissue. (a) Over expression of HMGB1 in
tumor tissue, HMGB1 immunostaining was predominantly located in cytoplasm of tumor cells (×400); (b) Low expression of HMGB1 in
para-tumor tissue (×400).
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of HMGB1 (p= 0.008). Factors not significantly affecting
overall survival included age, gender, HBV infection, AFP
level, underlying liver cirrhosis, Child-pugh classification,
tumor encapsulation and tumor differentiation. Multivari-
ate analysis showed that expression of HMGB1 (p= 0.009,
HR=1.834; 95%CI: 1.167-2.881) and tumor size
(p=0.005, HR=1.902; 95%CI: 1.209-2.992) were inde-
pendent prognostic factors for overall survival (Table 2).
The 1, 3, 5-year overall survival for patients with HMGB1
high expression was 83.9%, 53.8%, 38.2% respectively, and
89.1%, 72.4%, 61.7% respectively for patients with HMGB1
low expression (p=0.008, Figure 3).
The 1, 3, 5-year disease-free survival of the whole
group was 58.2%, 40.3% and 31.3% respectively. Univari-
ate analysis showed that tumor size (p= 0.004), tumor
number (p< 0.001), tumor encapsulation (p= 0.011),
TNM stage (p= 0.001) and expression of HMGB1
(p= 0.004) were prognostic factors for disease-free sur-
vival. Multivariate analysis indicated that expression of
HMGB1 (p= 0.018, HR= 1.622; 95%CI: 1.088-2.419) and
tumor size (p= 0.012, HR= 1.661; 95%CI: 1.119-2.465)
were independent prognostic factors for disease-free sur-
vival (Table 2). The 1, 3, 5-year disease-free survival for
patients with HMGB1 high expression was 48.6%, 29.0%,
21.0% respectively, and 65.7%, 49.1%, 39.9% respectively
for patients with HMGB1 low expression (p= 0.004,
Figure 3).
In subgroup analysis, for 76 patients with tumor >5 cm,
the 1, 3, 5-year overall survival for patients with HMGB1
high expression was 75.1%, 36.6%, 26.6% respectively, and
74.3%, 62.4%, 52.5% respectively for patients with HMGB1
low expression (p=0.031), the corresponding disease-free
survival was 34.5%, 14.6%, 14.6% respectively, and 52.9%,
40.0%, 32.0% respectively (p=0.012, Figure 4). However,
for patients with tumor ≤5 cm, the 1, 3, 5-year overall sur-
vival for patients with HMGB1 high expression was
91.7%, 68.9%, 48.5% respectively, and 91.8%, 81.2%, 69.8%
respectively for patients with HMGB1 low expression
(p=0.101), and the corresponding disease-free survivalwas 61.1%, 41.7%, 27.5% respectively, and 76.7%, 56.9%,
45.1% respectively (p= 0.087, Figure 4).
Discussion
In present study, we demonstrated that the expression of
HMGB1 was significantly higher in HCC tissue, com-
pared to that in para-tumor and normal liver tissue, high
expression of HMGB1 was significantly associated with
incomplete tumor encapsulation and advanced TNM
stage, and for the first time, we revealed that high expres-
sion of HMGB1 predicted poorer survival for patients
with HCC after curative hepatectomy, especially for
patients with tumor >5 cm. Our results were in agree-
ment with previous studies of other malignancies, includ-
ing gastric cancer, colorectal cancer, prostate cancer and
nasopharyngeal carcinoma et al, in which overexpression
of HMGB1 in tumor tissue has been observed and a cor-
relation between overexpression of HMGB1 and poorer
prognosis has been established [18-21].
There was increasing interest in the role of HMGB1 in
HCC in recent years. Cheng et al [25] firstly reported
the correlation between serum HMGB1 level and clini-
copathologic features in patients with HCC, higher
serum HMGB1 level correlated with bigger tumor size,
poor tumor differentiation and advanced TNM stage.
Then Jiang et al [22] reported that overexpression of
HMGB1 in tumor tissue, rather than in para-tumor and
normal tissue, correlate with advanced TNM stage, vas-
cular invasion and capsule invasion by detecting fresh
samples from 34 HCC patients. Similarly, our study,
with immunohistochemistry in a cohort of consecutive
161 previously untreated HCC, demonstrated that high
expression of HMGB1 was significantly associated with
incomplete tumor encapsulation and advanced TNM
stage. Since only the patients without vascular invasion
were enrolled, the correlation between the expression of
HMGB1 and vascular invasion cannot be analyzed in
present study.
Different models indicated the HMGB1 protein had
beneficial influence on tumor development. HMGB1
Table 2 Univariate and Multivariate analyses of overall and disease-free survival for 161 HCC patients
Variables Univariate analysis Multivariate analysis
Chi-Square (χ2) P value HR (95% CI) P value
Overall survival
Age(≤55y vs >55y) 0.453 0.501
Gender(male vs female) 1.875 0.171
HBV infection(absent vs present) 0.011 0.915
AFP level(≤400 ng/ml vs >400 ng/ml) 0.170 0.680
Liver cirrhosis(absent vs present) 1.631 0.202
Child-pugh(A vs B) 0.158 0.691
Tumor size(≤5 cm vs >5 cm) 7.962 0.005 1.902(1.209-2.992) 0.005
Tumor number(single vs multipule) 8.763 0.003 0.601(0.240-1.504) 0.277
Tumor encapsulation(complete vs incomplete) 2.590 0.108
TNM stage(I-II vs III) 8.484 0.004 1.567(0.771-3.184) 0.215
Tumor differentiation(I-II vs III-IV) 0.033 0.856
HMGB1(low vs high) 7.022 0.008 1.834(1.167-2.881) 0.009
Disease-free survival
Age(≤55y vs >55y) 0.812 0.367
Gender(male vs female) 0.120 0.729
HBV infection (absent vs present) 0.118 0.731
AFP level(≤400 ng/ml vs >400 ng/ml) 0.748 0.387
Liver cirrhosis(absent vs present) 1.972 0.160
Child-pugh(A vs B) 1.502 0.220
Tumor size(≤5 cm vs >5 cm) 8.367 0.004 1.661(1.119-2.465) 0.012
Tumor number(single vs multipule) 14.484 <0.001 0.484(0.218-1.071) 0.073
Tumor encapsulation(complete vs incomplete) 6.531 0.011 0.739(0.497-1.099) 0.136
TNM stage(I-II vs III) 11.494 0.001 1.314(0.719-2.402) 0.374
Tumor differentiation(I-II vs III-IV) 3.062 0.080 1.252(1.088-2.419) 0.291
HMGB1(low vs high) 8.176 0.004 1.622(1.088-2.419) 0.018
HBV: hepatitis B virus, AFP: alpha fetoprotein, HMGB1: high mobility group box 1, HR: Hazard Ratio.
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tumor cells, and also can be released by inflammatory
cells and by tumor cells [26]. Constant release of
HMGB1 as a proinflammatory cytokine from necrotic
tumor cells would create a microenvironment similar to
chronic inflammations, and this condition was known to
contribute to the development of epithelial malignancies
[27]. In present study, we conducted the RT-PCR, West-
ern blot and immunohistochemical methods to detect
the expression of HMGB1 in tumor, para-tumor and
normal tissues. Our results showed that the expression
of HMGB1 was significantly higher in tumor tissue than
that in para-tumor and normal tissue, which indicated
that HMGB1 might play an important part in the car-
cinogenesis of HCC.
HMGB1 can function during inflammation, tumor in-
vasion and metastasis through its receptors: RAGE and
TLRs. Liang et al [28] reported that knockdown ofRAGE inhibited expression of VEGF and SP1 protein in
colorectal cancer cells, and silence of RAGE expression
effectively inhibited colorectal cancer angiogenesis.
HMGB1 also takes part in immune system through
TLRs. TLRs exist in almost immunosuppressive cells
and recent study showed that tumor cell-derived
HMGB1 might suppress naturally acquired CD8 T cell-
dependent antitumor immunity via enhancing Treg to
produce IL-10, which is necessary for Treg-mediated im-
mune suppression [29]. These results indicated that
HMGB1 played an active role in tumor immune sup-
pression, which promoted the development of tumor in-
vasion and metastasis. In present study, we
demonstrated that high expression of HMGB1 was asso-
ciated with incomplete tumor encapsulation and
advanced TNM stage. Studies on other cancers also
showed that HMGB1 expression was positively corre-
lated with lymph node metastasis and distant metastasis.
a b
Figure 3 Overall and disease-free survival curves of 161 HCC cases after curative hepatectomy assessed by Kaplan–Meier analysis
according to HMGB1 expression. Patients with high expression of HMGB1 were significantly associated with poorer overall survival (a, p= 0.008)
and disease-free survival (b, p= 0.004).
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ciated with tumor growth and invasion [22].
Hepatectomy is the most effective curative therapy
and provides better survival outcomes for patients with
HCC. Unfortunately, approximately 33% of HCC
patients die within the first year even after curative sur-
gery, mainly because of tumor recurrence and spreada
Figure 4 Overall and disease-free survival curves assessed by Kaplan–
(a) Overall survival. High expression of HMGB1 predicted poorer overall sur
tumor ≤5 cm (group 1 VS group 2; p= 0.101). (b) Disease-free survival. High
tumor >5 cm (group 3 VS group 4; p = 0.012); but not for tumor ≤5 cm (g
expression (n = 49); group 2, tumor ≤5 cm/ HMGB1 high expression (n = 36
tumor >5 cm/ HMGB1 high expression (n = 33).[2,3]. Currently, prognostic evaluation is mainly based
on tumor stage and histopathologic observation such
as tumor size, tumor number, and vascular invasion [1-
4]. However, we found that although patients have
modest tumor presentation, the prediction for patients’
overall and disease-free survival can be variable and in-
accurate. Recent studies have suggested some factors,b
Meier analysis according to HMGB1 expression and tumor size.
vival only for tumor >5 cm (group 3 VS group 4; p= 0.031); but not for
expression of HMGB1 predict poor disease-free survival only for
roup 1 VS group 2; p = 0.087). Group 1, tumor ≤5 cm/ HMGB1 low
); group 3, tumor >5 cm/ HMGB1 low expression (n = 43); group 4,
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mary tumor, may improve our ability to prognosticate
[4]. In present study, the expression of HMGB1 was
revealed as an independent prognostic factor for both
overall and disease-free survival for patients with HCC
after curative hepatectomy. The patients with high ex-
pression of HMGB1 had a shorter overall and disease-
free survival. More importantly, subgroup analysis
showed the expression of HMGB1 was significantly
associated with poor prognosis in patients with HCC
>5 cm, but not in patients with HCC ≤5 cm. Studies
in other cancers, including colorectal cancer, nasopha-
ryngeal carcinoma, and squamous-cell carcinoma of the
head and neck, also showed that HMGB1 expression
was inversely correlated with survival in late stage can-
cers but not in early stage caners [18-21]. This trend
suggested that HMGB1 might be an important prog-
nostic marker for late stage HCC after hepatectomy.
However, prospective clinical studies are needed to
confirm that HMGB1 is one of the reliable clinical pre-
dictors of outcome for individual patients with HCC
undergoing hepatectomy.
Conclusions
In conclusion, our study revealed that HMGB1 is an in-
dependent prognostic factor for overall and disease-free
survival in patients with HCC after curative hepatect-
omy. High expression of HMGB1 in tumor is strongly
correlated with incomplete tumor encapsulation and
advanced TNM stage. However, these results, which are
based on a Chinese cohort (all surgical patients without
vascular invasion and mostly associated with HBV infec-
tions), should be further confirmed in other populations
of patients with HCC. Our findings suggest that HMGB1
might be used as a new biomarker and a potential thera-
peutic target for HCC.Abbreviations
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